Clicky

DICE Therapeutics, Inc.(DICE)

Description: DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It designs and develops therapies in immunology for patients with chronic diseases. The company's lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin and aVß1/aVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis. The company was founded in 2013 and is headquartered in South San Francisco, California.


Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Health Sciences Inflammation Chronic Disease Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Interleukin 17

Home Page: www.dicemolecules.com

DICE Technical Analysis

279 East Grand Avenue
South San Francisco, CA 94080
United States
Phone: 650 566 1402


Officers

Name Title
Dr. J. Kevin Judice Ph.D. Founder, CEO & Director
Mr. Scott Robertson Chief Bus. & Financial Officer
Dr. Timothy Lu M.D., Ph.D. Chief Medical Officer
Dr. John R. Jacobsen Ph.D. Chief Scientific Officer
Ms. Mary Riley J.D. Gen. Counsel
Mr. Venkat Thalladi Ph.D. Sr. VP of CMC
Mr. Paul Fatheree Sr. VP of Medicinal Chemistry

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 11.3409
Price-to-Book MRQ: 5.9124
Price-to-Sales TTM: 699.0015
IPO Date: 2021-09-15
Fiscal Year End: December
Full Time Employees: 65
Back to stocks